{"entity":{"id":"paltusotine","kind":"drug","name":"Paltusotine","aka":["CRN00808"],"tldr":"Paltusotine is the first somatostatin-type drug that works as a once-daily pill instead of a monthly injection. It was approved in 2025 for acromegaly and is being tested for the flushing and diarrhoea of carcinoid syndrome from small-bowel neuroendocrine tumours.","summary":"Paltusotine is Crinetics Pharmaceuticals' oral, non-peptide agonist of somatostatin receptor 2. In the phase 3 PATHFNDR trials in acromegaly it maintained IGF-1 control in patients switched from injected somatostatin analogues and achieved control in untreated patients, and the FDA approved it in September 2025 for the treatment of acromegaly in adults.\n\nCarcinoid syndrome depends on the same receptor: the phase 3 CAREFNDR trial is testing paltusotine against placebo for flushing and bowel frequency in patients with carcinoid syndrome from neuroendocrine tumours. The small intestinal neuroendocrine tumour page names it, with a subcutaneous octreotide depot, among the symptom-control options in development after the injected analogues.","status":"approved","asOf":"2026-09-17","links":[],"tags":["subtype-drugs-wave"],"related":["octreotide-lanreotide"],"cancers":["small-intestinal-net"],"sections":[],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":["crinetics-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Palsonify","modality":"Oral non-peptide somatostatin receptor 2 agonist","mechanism":"A small molecule that selectively activates somatostatin receptor 2, the receptor through which octreotide and lanreotide suppress growth hormone and the hormones that cause carcinoid syndrome, but taken as a once-daily tablet rather than an injection.","approvals":[{"region":"US","year":2025,"indication":"Acromegaly in adults"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/paltusotine/","neighbours":{"drug":[{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/"}],"cancer":[{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/"}]}}